Oxytocin on Cold Water Task Performance and Recovery

Sponsor
Florida Institute for Human and Machine Cognition (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04738838
Collaborator
Office of Naval Research (ONR) (U.S. Fed), University of Florida (Other)
24
2
2
24
12
0.5

Study Details

Study Description

Brief Summary

Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community.

Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.

Condition or Disease Intervention/Treatment Phase
  • Drug: Oxytocin nasal spray
  • Drug: Placebo nasal spray
Phase 2

Detailed Description

Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community.

Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.

Cold water operators undergo an extensive and unique set of physical, physiological, and psychological stressors during a mission. In-water transit may exceed 6 hours submerged in cold water, on rebreathers, and in a confined space. During this lengthy transit, operators must maintain vigilance over navigation, vehicle, and life support controls while exposed to the risks of mixed gas or oxygen rebreather diving, alongside hypothermia, dehydration, undernutrition, and other factors that can significantly degrade operator performance. Once the team has reached target, they must be at peak cognitive and physical readiness as they carry out their mission objective. When the mission objective is complete, the operators undertake the lengthy return trip back to their deployed base. Optimized operator cognitive and physical performance is essential throughout all phases of a cold water mission, and safe and tolerable approach to optimizing warfighter performance and resilience will be key for future cold water operations.

Given the potential thermogenic and recovery effects or intranasal OT, we hypothesize that prophylactic OT administration, compared to placebo, will mitigate deficits in mission-relevant performance during and after cold water exposure. For this project we will utilize the ONR Cold Water Performance Task Battery, which was designed based on results from a task analysis combined with input from the cold water operator community. The task battery has been validated for its ability to induce changes in core and peripheral body temperature, manual dexterity, cognitive performance, and physical performance following cold water exposure. Our hypothesis will be tested via one specific aim enrolling N=24 18-39 y/o men by using a rigorous, double-blind, placebo- controlled, within-subjects randomized cross-over trial comparing 48 IU OT vs placebo (saline) in cold water performance and recovery.

Specific Aim 1. To investigate the impact of intranasal OT on cold water task performance and recovery using the ONR Cold Water Performance Task Battery, which includes cold water exposure; cognitive performance testing via oculometric assessment and the Defense Automated Neurobehavioral Assessment (DANA); and physical performance testing via a simulated ruck, ladder climb, and manual dexterity testing.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Double-blind, placebo-controlled, randomized crossover designDouble-blind, placebo-controlled, randomized crossover design
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
All will remain blinded until completion of human subjects data collection except the research pharmacist providing intranasal oxytocin or placebo.
Primary Purpose:
Prevention
Official Title:
Evaluating Potential Benefits of Intranasal Oxytocin on Undersea Operator Training and Performance: Cold Water Task Performance and Recovery
Anticipated Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oxytocin Nasal Spray

Single dose of intranasal oxytocin (48 IU) prior to testing protocol.

Drug: Oxytocin nasal spray
Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
Other Names:
  • Oxytocin
  • Placebo Comparator: Placebo Nasal Spray

    Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)

    Drug: Placebo nasal spray
    Intranasal treatment with placebo via nasal spray
    Other Names:
  • Placebo
  • Outcome Measures

    Primary Outcome Measures

    1. Cognitive performance assessment score change (code substitution) [Within 3 hours post-treatment]

      Changes in code substitution scores as measured by the Defense Automated Neurobehavioral Assessment (DANA). Data will be measured in milliseconds for response time.

    2. Cognitive performance assessment score change (code substitution) [Within 3 hours post-treatment]

      Changes in code substitution scores as measured by the Defense Automated Neurobehavioral Assessment (DANA). Data will be measured in number of correct or incorrect responses.

    3. Cognitive performance assessment score change (reaction time) [Within 3 hours post-treatment]

      Changes in choice reaction time scores as measured by the Defense Automated Neurobehavioral Assessment (DANA). Data will be measured in milliseconds for response time.

    4. Cognitive performance assessment score change (reaction time) [Within 3 hours post-treatment]

      Changes in choice reaction time scores as measured by the Defense Automated Neurobehavioral Assessment (DANA). Data will be measured in number of correct or incorrect responses.

    5. Oculometric assessment score change (saccades) [Within 3 hours post-treatment]

      Altered ocular response as measured by the I-Portal Portable Assessment System (i-PAS). Saccades will be monitored and counted throughout the duration of the assessment.

    6. Oculometric assessment score change (blink rate) [Within 3 hours post-treatment]

      Altered ocular response as measured by the I-Portal Portable Assessment System (i-PAS). Number of blinks will be counted through the course of the assessment.

    7. Oculometric assessment score change (blink duration) [Within 3 hours post-treatment]

      Altered ocular response in blink duration as measured by the I-Portal Portable Assessment System (i-PAS). Blink duration will be measured in milliseconds.

    Secondary Outcome Measures

    1. Reduced rating of perceived exertion (RPE) during physical assessment post-cold water exposure [Within 3 hours post-treatment]

      Participants will signal on the Borg (6-20) scale for whole body and lower body exertion following their exposure to cold water. Lower on the scale signal a lower level of perceived physical exertion.

    Other Outcome Measures

    1. Difference in grip strength in cold water [Within 3 hours post-treatment]

      During and after cold water exposure, participants will complete a grip strength assessment through the use of a hand dynamometer. Measurements will be taken in Newtons.

    2. Difference in manual dexterity (underwater knot untying) in cold water [Within 3 hours post-treatment]

      During and after cold water exposure, participants will complete a timed underwater knot untying and peg board time trial. Measurement will be recorded in seconds.

    3. Difference in manual dexterity (underwater peg board assessment) in cold water [Within 3 hours post-treatment]

      During and after cold water exposure, participants will complete a timed underwater peg board assessment time trial. Measurement will be recorded in seconds.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 39 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Recreationally skilled swimmers
    Exclusion Criteria:
    • Smoking/vaping, a history of psychiatric disorders, safety requirements related to the oxytocin administration [hypersensitivity to oxytocin or vasopressin, history of hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, or psychogenic polydipsia, on vasoconstrictors such as desmopressin, pseudoephedrine, or antidiuretic medication, or anti-inflammatory drugs, or muscle relaxants, low sodium and high osmolality levels, excessive smoking, excessive drinking, and significant nasal pathology.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Florida Gainesville Florida United States 32611
    2 Florida Institute for Human and Machine Cognition Pensacola Florida United States 32502

    Sponsors and Collaborators

    • Florida Institute for Human and Machine Cognition
    • Office of Naval Research (ONR)
    • University of Florida

    Investigators

    • Principal Investigator: Thaddeus Light, Ph.D., Florida Institute for Human and Machine Cognition

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Florida Institute for Human and Machine Cognition
    ClinicalTrials.gov Identifier:
    NCT04738838
    Other Study ID Numbers:
    • IRB-2020-0002
    First Posted:
    Feb 4, 2021
    Last Update Posted:
    Feb 4, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 4, 2021